Hypertension, Nitric Oxide, and Beta-BlockadeCME/CE Following the ASCOT results, beta-blockers were downgraded as frontline antihypertensives. But does this mean all beta-blockers? Why does it appear that the newer ones should be retained?
New Data on First-in-Class Oral Renin Inhibitor, Aliskiren ASH 2006: The first new antihypertensive modality in 10 years targets the renin-angiotensin-aldosterone system (RAAS) at its point of activation, and several data presentations at the 2006 ASH meeting delineate its promise.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hypertension. These materials and the related activity are not sanctioned by the American Society of Hypertension or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
